TNX-355 Poster Presentations at ICAAC Scheduled, Tanox to Host Briefing for Investors and Analysts
Posted on: Wednesday, 7 December 2005, 21:00 CST
HOUSTON, Dec. 7 /PRNewswire-FirstCall/ -- Tanox, Inc. will have two poster presentations on its HIV viral-entry inhibitor antibody, TNX-355, at the American Society for Microbiology's Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Dec. 16-19, 2005 in Washington, D.C.
The presentations will be made Dec. 17, from 1:30 to 3 p.m., EST, at the Washington Convention Center (Poster Board BA in Hall B). Phase 2 Week 24 efficacy results will be highlighted, in addition to TNX-355's activity against CCR5 and CXCR4 viruses and results of in vitro combination studies with enfuvirtide.
Tanox will host an investor/analyst briefing in Washington following the poster session. The briefing is scheduled from 4 to 5 p.m., EST, and will be accessible by conference call for those unable to attend. To join the conference call, dial 1-866-800-8652 (access code 3879-5703).
About TNX-355
TNX-355 is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing the entry of HIV particles into lymphocytes. TNX-355 is the first antibody in development for the treatment of HIV and AIDS. A Phase 2 clinical study demonstrated that TNX-355, plus optimized background therapy, produces a clinical meaningful reduction in viral load against multiple strains of HIV, without depleting CD4-positive cells. TNX-355 was fast tracked by the Food and Drug Administration in 2003. The fast-track designation expedites approval of therapies for life-threatening diseases and allows for rolling new drug application (NDA) submissions.
About Tanox, Inc.
Tanox is a biotechnology company specializing in the discovery and development of monoclonal antibodies. The company develops innovative biotherapeutics for the treatment of immune-mediated diseases, inflammation, infectious disease and cancer. Tanox's lead investigational therapy, TNX-355, is viral-entry inhibitor antibody to treat HIV/AIDS. TNX-355 has shown significant antiretroviral activity in Phase 2 clinical testing. Tanox's first-approved drug, Xolair(R) (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed, allergic asthma. Xolair was developed in collaboration with Genentech, Inc. and Novartis Pharma AG and is currently approved for marketing in the United States, Canada and major European countries. Tanox is based in Houston and has a manufacturing facility in San Diego. Additional corporate information is available at http://www.tanox.com/.
Photo: http://www.newscom.com/cgi-bin/prnh/20050207/TNOXLOGOPRN Photo Desk, photodesk@prnewswire.com
Tanox, Inc.
CONTACT: Steve Sievert of Tanox, Inc., +1-713-578-4211, orssievert@tanox.com
Web site: http://www.tanox.com/
Source: PRNewswire-FirstCall
Related Articles
- OraSure to Launch OraQuick Advance Rapid HIV-1/2 Antibody Test Directly in US
- OraSure Technologies to Sell OraQuick ADVANCE Rapid HIV-1/2 Antibody Test Directly to U.S. Hospitals
- Nationwide Data Indicate a Very High Degree of Accuracy for OraQuick ADVANCE Rapid HIV-1/2 Antibody Test With Oral Fluid
- OraSure Technologies Signs Purchase Contract With New York City Department of Mental Health and Hygiene for OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Tests
- Washington, DC Launches City-Wide HIV Testing and Prevention Campaign With OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test
- Halozyme Therapeutics Presents Preclinical and Pharmacokinetic Data on the Subcutaneous Delivery of Antibodies With Enhanze Technology at the 2006 IBC Antibody Conference
- Novation Signs Single Source Agreement for OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test
- Monoclonal Antibodies Conference to Feature Latest Advances on Big Pharma Collaborative Program, Cetuximab, Sept. 26-27, Phila, PA
- Vaccine in Cancer Fight Approved for Clinical Trials
- Chinese Anti-Cancer Vaccine Approved for Clinical Research
 |
 |
User Comments (0)
RSS Feeds